France Dry Age-Related Macular Degeneration (AMD) Market Size, Share, and COVID-19 Impact Analysis, By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, and Late Age-Related Macular Degeneration), By Route of Administration (Oral and Injectables), and France Dry Age-Related Macular Degeneration (AMD) Market Insights, Industry Trend, Forecasts to 2035

France Dry Age-Related Macular Degeneration (AMD) Market Insights Forecasts to 2035

• The France Dry Age-Related Macular Degeneration (AMD) Market Size was Estimated at USD 203.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.26% from 2025 to 2035
• The France Dry Age-Related Macular Degeneration (AMD) Market Size is Expected to Reach USD 486.0 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The France Dry Age-Related Macular Degeneration (AMD) Market Size is anticipated to Reach USD 486.0 Million by 2035, Growing at a CAGR of 8.26% from 2025 to 2035. The growth is driven by the aging population of France, increased awareness of retinal health, and easier access to eye care.  Further promoting early detection and long-term disease management are developments in diagnostic technologies and new treatments, such as telemedicine and nutraceuticals.

Market Overview

The France Dry Age-Related Macular Degeneration (AMD) Market Size refers to the healthcare and treatment landscape centered on managing dry AMD, a chronic, progressive eye condition that affects the macula and causes gradual central vision loss, in older adults, is referred to as the France dry age-related macular degeneration (AMD) market. Additionally, the French healthcare system, which is renowned for its universal coverage, is adjusting to meet the needs of individuals afflicted by this condition. This includes extending access to preventive measures and ophthalmological care. Opportunities are being created in the French market by new technologies like telemedicine and changing treatment options.  Access to doctor consultations is being improved by telemedicine, particularly in rural areas.  As patients search for methods to control their condition, emerging therapies such as drug treatments and nutraceuticals are also gaining popularity.  Furthermore, French pharmaceutical companies and research institutions are working together more frequently to develop clinical trials and more effective treatment modalities that could improve patient outcomes.  In France, there has been a noticeable change recently toward patient education and support.

Report Coverage

This research report categorizes the market for the France dry age-related macular degeneration (AMD) market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France dry age-related macular degeneration (AMD) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France dry age-related macular degeneration (AMD) market.

Driving Factors

The market for dry age-related macular degeneration (AMD) in France is being greatly impacted by increased awareness of the condition and thorough screening programs.  To reduce the risk of AMD, a number of health campaigns, including those started by the French Ophthalmology Society, stress the significance of early detection and lifestyle changes.  These programs, which promote routine eye exams, are increasing the number of diagnoses, which in turn increases the demand for available treatments. These awareness campaigns have been linked to a reported 30% increase in AMD diagnoses over the course of five years, which directly affects market growth as more patients seek therapeutic interventions.

Restraining Factors

The market for dry AMD in France is constrained by high treatment costs, few therapeutic options, sluggish disease progression, and low patient awareness.  Furthermore, delayed diagnosis and unequal access to healthcare lower early intervention rates, which affects market expansion and the uptake of new technologies.

Market Segmentation

The France dry age-related macular degeneration (AMD) market share is classified into stage and route of administration.

• The intermediate age-related macular degeneration segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France dry age-related macular degeneration (AMD) market is segmented by stage into early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Among these, the intermediate age-related macular degeneration segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Patients with intermediate age-related macular degeneration start to noticeably alter their vision, so risk mitigation requires careful monitoring and management.  This stage is crucial for detecting patients who might advance to the more severe stage of late age-related macular degeneration, which has a major influence on day-to-day functioning.

• The injectables segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France dry age-related macular degeneration (AMD) market is segmented by route of administration into oral and injectables. Among these, the injectables segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The significance of injectables in effectively treating more severe forms of AMD is highlighted by the fact that they are necessary for precisely administering doses straight into the eye. The injectables have a significant market share because they are frequently preferred in clinical practice due to their quick action and efficiency in halting the progression of the disease.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France dry age-related macular degeneration (AMD) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sanofi
• Servier Laboratories
• Horus Pharma
• Thea Pharmaceuticals
• GenSight Biologics
• Innoveox
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France Dry Age-Related Macular Degeneration (AMD) Market based on the below-mentioned segments:

France Dry Age-Related Macular Degeneration (AMD) Market, By Stage

• Early Age-Related Macular Degeneration
• Intermediate Age-Related Macular Degeneration
• Late Age-Related Macular Degeneration

France Dry Age-Related Macular Degeneration (AMD) Market, By Route of Administration

• Oral
• Injectables